Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 56,376	$ 62,957
Operating expenses:
Cost of revenue	59	1,907
Research and development	100,125	157,643
Selling, general and administrative	36,273	46,778
Total operating expenses	136,457	206,328
Loss from operations	(80,081)	(143,371)
Other income:
Change in fair value of equity investments	(5,915)	(13,103)
Interest income	21,283	21,307
Other expense, net	(287)	(8,021)
Total other income	15,081	183
Loss before (provision for) benefit from income taxes	(65,000)	(143,188)
(Provision for) benefit from income taxes	(276)	2,232
Net loss	(65,276)	(140,956)
Net loss attributable to noncontrolling interest	0	(56)
Net loss attributable to Vir	$ (65,276)	$ (140,900)
Net loss per share attributable to Vir, basic (in USD per share)	$ (0.48)	$ (1.06)
Net loss per share attributable to Vir, diluted (in USD per share)	$ (0.48)	$ (1.06)
Weighted-average shares outstanding, basic (in shares)	135,280,648	133,552,839
Weighted-average share outstanding, diluted (in shares)	135,280,648	133,552,839
Collaboration revenue
Revenues:
Total revenues	$ (987)	$ 46,574
Contract revenue
Revenues:
Total revenues	52,191	138
Grant revenue
Revenues:
Total revenues	$ 5,172	$ 16,245